Abstract
Parkinson’s disease (PD) and cancer are often thought of as two sides of the same coin. At first glance, cancer and PD appear to have little in common. PD is caused by the degeneration of dopaminergic neurons, whereas cancer results from the uninhibited growth of tumor cells. Increasing numbers of genetic studies suggest that the pathogenesis of PD and cancer may involve similar genes, pathways, and mechanisms. The differences in the pathological and cellular mechanisms, and the associated genetic mutations, may result in two such divergent diseases. In this article, we highlight some molecular mechanisms and key biomarkers which might cause those two diseases from misfolding and degradation of proteins, mitochondrial damage, oxidative stress response, cell cycle control and DNA repair, and the PI3K/AKT/ mTOR pathway, in order to provide help to the understanding and treatment of these two diseases.
Keywords: Cancer, genes, parkinson’s disease, pathways.
Current Cancer Drug Targets
Title:Genetic Predisposition to Parkinson’s Disease and Cancer
Volume: 14 Issue: 3
Author(s): Zhiming Li, Qing Lin, Qilin Ma, Congxia Lu and Chi-Meng Tzeng
Affiliation:
Keywords: Cancer, genes, parkinson’s disease, pathways.
Abstract: Parkinson’s disease (PD) and cancer are often thought of as two sides of the same coin. At first glance, cancer and PD appear to have little in common. PD is caused by the degeneration of dopaminergic neurons, whereas cancer results from the uninhibited growth of tumor cells. Increasing numbers of genetic studies suggest that the pathogenesis of PD and cancer may involve similar genes, pathways, and mechanisms. The differences in the pathological and cellular mechanisms, and the associated genetic mutations, may result in two such divergent diseases. In this article, we highlight some molecular mechanisms and key biomarkers which might cause those two diseases from misfolding and degradation of proteins, mitochondrial damage, oxidative stress response, cell cycle control and DNA repair, and the PI3K/AKT/ mTOR pathway, in order to provide help to the understanding and treatment of these two diseases.
Export Options
About this article
Cite this article as:
Li Zhiming, Lin Qing, Ma Qilin, Lu Congxia and Tzeng Chi-Meng, Genetic Predisposition to Parkinson’s Disease and Cancer, Current Cancer Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1568009614666140312145936
DOI https://dx.doi.org/10.2174/1568009614666140312145936 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial
Current Cancer Therapy Reviews Proteomic Approaches for the Study of Transgelins as Tumor-associated Proteins and Potential Biomarkers
Current Proteomics LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry Mechanism and Anticancer Activity of the Metabolites of an Endophytic Fungi from Eucommia ulmoides Oliv
Anti-Cancer Agents in Medicinal Chemistry Novel Prodrugs for the Treatment of Colonic Diseases Based on 5-Aminosalicylic Acid, 4'-eranyloxyferulic Acid, and Auraptene: Biological Activities and Analytical Assays
Current Drug Delivery Gallium-68 in Medical Imaging
Current Radiopharmaceuticals Recent efforts toward the development of peptide secondary structure mimetics at Molecumetics Ltd. for the discoveries of new drug candidates utilizing combinatorial chemistry with solid phase synthesis are described
Combinatorial Chemistry & High Throughput Screening Working Towards the Development of Vaccines for the Treatment and Prevention of Early Breast Cancer
Current Cancer Therapy Reviews The Endothelial-Mesenchymal Transition (EndMT) and Tissue Regeneration
Current Stem Cell Research & Therapy Exploring the Molecular Function of PIN1 by Nuclear Magnetic Resonance
Current Protein & Peptide Science Synthesis of New Thioureas Derivatives and Evaluation of Their Efficacy as Proliferation Inhibitors in MCF-7 Breast Cancer Cells by Using <sup>99m</sup>Tc-MIBI Radiotracer
Medicinal Chemistry Caveats Regarding the Use of IL-10 and IL-10 Antagonist as Immunotherapeutic Factors
Letters in Drug Design & Discovery Induction of Apoptosis by Curcumin and Its Implications for Cancer Therapy
Current Cancer Drug Targets Molecular Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Hemodialysis Patients
Current Signal Transduction Therapy C-20 Cyclopropyl Vitamin D3 Analogs
Current Topics in Medicinal Chemistry The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Current Pediatric Reviews Subject Index To Volume 12
Current Pharmaceutical Design Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues
Anti-Cancer Agents in Medicinal Chemistry EDITORIAL (Hot Topic: “Signal Transduction and Response to Anti-Cancer Therapy”)
Current Signal Transduction Therapy